[SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].

Tirzepatide (10 or 15 mg/week) is associated with a reduction in body weight and improvements in sleep apnoea parameters.

• Tirzepatide may diminish the frequency and severity of sleep apnoea episodes.
• There could be a reduction in hypoxia burden and arterial blood pressure.
• Systemic inflammation may be lowered with tirzepatide treatment.
• Patients reported improved sleep quality while using tirzepatide.
• The study focused on individuals with obesity and obstructive sleep apnoea.

AI simplified